14 September 2017
Arix Bioscience to Host Capital Markets Meeting in London, 18 September 2017
LONDON, 14 September, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, will host its inaugural Capital Markets Meeting for investors and analysts in London on 18 September 2017.
Dr Joe Anderson, Chief Executive Officer of Arix Bioscience, and Jonathan Peacock, Chairman of Arix Bioscience, will provide an update on the Company’s strategy and progress to date. The event will also include presentations from a number of Arix Group Businesses regarding their objectives, progress and potential.
The meeting will be held at Etc. venues 8 Fenchurch Place, Fenchurch Street, London EC3M 4PB, from 12:30 to 18:00 BST. There will be a series of short presentations, question and answer sessions, and networking. No new material information will be disclosed.
Presenters at the Arix Capital Markets Meeting will include:
- Jonathan Peacock, Chairman of Arix Bioscience plc
- Joe Anderson PhD, CEO of Arix Bioscience plc
- Christian Itin PhD, CEO and Chairman of Autolus
- Gerald McMahon PhD, President and CEO of Harpoon Therapeutics
- Niall Martin PhD, CEO of Artios Pharma
- Gordon Hamilton MA MD MBBS MBA, CEO of Depixus
- Corey Fishman MSM, CEO of Iterum Therapeutics
- Mike Moran MBE, CEO of Proton Partners International
A live webcast of the event, with presentation slides, will be available from 13:30 BST (08:30 Eastern Time) on the Arix website at https://arixbioscience.com. A replay will be available on the website shortly after the event.
For more information, please contact:
Arix Bioscience plc
Joe Anderson, CEO
+44 (0) 20 7290 1052
Matthew Cole, Communications Director
+44 (0) 20 7290 1065
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.
For further information, please visit www.arixbioscience.com